Liraglutide for Type 2 Diabetes
Research, mechanism, dosing, and effectiveness of Liraglutide for type 2 diabetes.
Quick Answer
Liraglutide (Victoza) is FDA-approved for type 2 diabetes with A1C reductions of 1-1.5%.
Evidence Level
FDA Approved
Typical Dose
1.2-1.8 mg daily for diabetes
Results Timeline
Blood sugar improvements within 2-4 weeks
FDA Status
FDA Approved
How Liraglutide Works for Type 2 Diabetes
GLP-1 enhances insulin secretion and reduces glucagon release.
About Type 2 Diabetes
Management of blood glucose levels and insulin sensitivity in type 2 diabetes.
Research Evidence
SCALE trials showed 5-10% weight loss. LEADER trial demonstrated cardiovascular benefits in diabetics. Extensive long-term safety data available. First GLP-1 approved specifically for weight management (Saxenda).
Dosing for Type 2 Diabetes
Recommended Dose
1.2-1.8 mg daily for diabetes
Frequency
Once daily
Administration
Subcutaneous injection daily
Duration
Long-term / chronic use
Note: FDA-approved GLP-1. Daily injection. Victoza (diabetes) or Saxenda (weight loss). Titrate up weekly.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (common)
- •Vomiting
- •Diarrhea
- •Constipation
- •Headache
- •Hypoglycemia (with insulin/sulfonylureas)
Frequently Asked Questions
Does Liraglutide help with type 2 diabetes?
Liraglutide (Victoza) is FDA-approved for type 2 diabetes with A1C reductions of 1-1.5%.
How does Liraglutide work for type 2 diabetes?
GLP-1 enhances insulin secretion and reduces glucagon release....
What dose of Liraglutide should I use for type 2 diabetes?
1.2-1.8 mg daily for diabetes
How long until I see results?
Blood sugar improvements within 2-4 weeks
Other Peptides for Type 2 Diabetes
These peptides are also researched for type 2 diabetes.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Cagrilintide
Clinical TrialsA long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Tirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Dulaglutide
FDAAn FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Educational Information Only
This information about Liraglutide for type 2 diabetes is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.